It’s all upside now. All bad news has been accounted for. All cost has been expensed and all expectations(for csl112) have been flattened . If any benefit can be found for a subset of patients it is pure upside.
meanwhile all csl forecasts have always, and continue to, exclude any contribution. .
Ann: Top-line Results from the Phase 3 AEGIS-II Trial, page-23
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.87 |
Change
5.070(1.76%) |
Mkt cap ! $142.0B | |||
| Open | High | Low | Value | Volume |
| $289.10 | $294.19 | $289.07 | $248.0M | 846.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 96 | $293.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.88 | 4960 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |